BeOne Medicines AG (6160.HK)
50.4Fair
ValueMarkers Composite Index
Top 45%#25,218 of 45,555
DCF data not available
Piotroski
7/9
StrongBeneish
-2.21
InvestigateAltman
44.05
SafeDCF Value
-
N/AROIC
4.8%
LowP/E
120.0
GrowthUpdated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Deep Dive Analysis
DCF Analysis
Intrinsic value estimate, margin of safety, and key valuation metrics.
DCF: $-2609.85Graham: $3.70
Piotroski F-Score
9-point financial strength test across profitability, leverage, and efficiency.
F-Score: 7/9
Quality Triple Check
Piotroski F-Score + Altman Z-Score + Beneish M-Score combined assessment.
F: 7/9Z: 44.0M: -2.2
Valuation Analysis
Complete multiples breakdown - P/E, P/B, EV/EBITDA, yield metrics, and intrinsic value.
P/E: 120.0P/B: 7.9EV/EBITDA: 55.1